Despite having relatively little funding available, the Global Fund Board has approved 85 Round 9 grants that will cost up to $1.99 billion over the first two years. This makes Round 9 the Fund's second largest round, after Round 8. In addition (see article 3, below), the Board approved five "National Strategy Applications" that will cost $0.39 billion over the first two years. The total two-year approved amount for the two groups of grants is $2.38 billion.
Also Round 10 will, subject to board confirmation in April 2010, be launched at the start of May 2010.
These decisions were made at the Fund's twentieth board meeting, held on November 9-11 in Addis Ababa, Ethiopia.
If the Fund were to follow the policies and practices that it followed before Round 8, it would have well under half the money it needs to approve these proposals. After extensive negotiation, the Board handled this by introducing a number of measures to reduce or delay costs, as follows:
Even with implementation of the above measures, the Fund does not currently have enough money to pay for the Round 9 proposals that were rated Category 2B by the TRP. However, the Fund is solidly confident that it will have sufficient funding for these proposals by some point in 2010. Accordingly, following a procedure that it has used several times before, the Board agreed to a system for prioritizing when the Category 2B proposals can be formally approved. (For details, see the next article.)
The Board's decisions as to which proposals to approve was, as always, entirely based on the advice it received from the TRP, an independent and non-political body of 40 experts from around the world who serve in their personal capacities. No Board members or Secretariat employees are members of the TRP.
In another key decision regarding future grants, the Board resolved that its "Rolling Continuation Channel", whereby expiring grants can be renewed, will be discontinued immediately.
And regarding Round 10, the Board decided that subject to confirmation at its next board meeting in April 2010, the Fund will issue the Round 10 call for proposals on or about 1 May 2010. Proposals must be submitted by 1 August 2010, and the board will decide which ones to approve between November 2010 and January 2011.
Some of the highlights of Round 9 approvals were as follows:
The following tables summarize Round 9 results.
Table 1: Global Fund Proposals, Submitted and Approved, by Round| Round | Eligible proposals submitted | Of which, approved by Board | Average cost of submitted proposals | Average cost of approved proposals | ||||
| Number | Cost * | Number (and % of submitted number) | Cost * (and % of submitted cost) | |||||
| Round 1 | 204 | $1.5 b. | 58 | (28%) | $0.6 b. | (38%) | $7 m. | $10 m. |
| Round 2 | 229 | $2.1 b. | 98 | (43%) | $0.9 b. | (40%) | $9 m. | $9 m. |
| Round 3 | 180 | $1.8 b. | 71 | (39%) | $0.6 b. | (33%) | $10 m. | $9 m. |
| Round 4 | 173 | $2.5 b. | 69 | (40%) | $1.0 b. | (39%) | $15 m. | $14 m. |
| Round 5 | 202 | $3.3 b. | 63 | (31%) | $0.7 b. | (22%) | $16 m. | $12 m. |
| Round 6 | 196 | $2.5 b. | 85 | (43%) | $0.8 b. | (34%) | $13 m. | $10 m. |
| Round 7 | 150 | $2.4 b. | 73 | (49%) | $1.1 b. | (47%) | $16 m. | $15 m. |
| Round 8 | 174 | $5.8 b. | 94 | (54%) | $3.1 b. | (51%) | $33 m. | $33 m. |
| Round 9 | 159 | $4.8 b. | 85 | (53%) | $2.2 b. | (46%) | $31 m. | $26 m. |
* Note: In this and the following tables, "Cost" means the amount requested for Years 1 to 2 (i.e. for Phase 1). In the case of Round 9, as discussed above, and also for Round 8, the total amount that the Board agreed to pay was ten percent less than this. Cost does not include proposals approved under the RCC option, or proposals only approved upon appeal.
Table 2: Disease Component Results by Round| Number of eligible proposals submitted, number approved, and % of submitted proposals approved | Cost of approved proposals, and % split between disease components | ||||||||||||||
| Round 7 | Round 8 | Round 9 | Round 7 | Round 8 | Round 9 | ||||||||||
| HIV/AIDS | 64 | 26 | 41% | 76 | 37 | 49% | 74 | 35 | 47% | $0.54 b. | 48% | $1.16 b. | 38% | $0.98 b. | 44% |
| Malaria | 45 | 28 | 62% | 41 | 28 | 68% | 31 | 17 | 55% | $0.47 b. | 42% | $1.57 b. | 51% | $0.61 b. | 28% |
| TB | 41 | 19 | 46% | 57 | 29 | 51% | 54 | 33 | 61% | $0.11 b. | 10% | $0.33 b. | 11% | $0.62 b. | 28% |
| Total | 150 | 73 | 49% | 174 | 94 | 54% | 159 | 85 | 53% | $1.12 b. | 100% | $3.06 b. | 100% | $2.21 b. | 100% |
| Region | Number of proposals submitted | Number approved | Percent of submitted proposals approved | Cost of approved proposals | Percent split between regions | |||||
| R8 | R9 | R8 | R9 | R8 | R9 | R8 | R9 | R8 | R9 | |
| Africa: Eastern | 21 | 16 | 13 | 8 | 62% | 50% | $0.80 b. | $0.38 b. | 26% | 17% |
| Africa: Southern | 17 | 13 | 10 | 7 | 59% | 54% | $0.41 b. | $0.26 b. | 13% | 12% |
| Africa: West and Central | 30 | 32 | 17 | 18 | 57% | 56% | $0.91 b. | $0.59 b. | 30% | 27% |
| East Asia and the Pacific | 20 | 17 | 15 | 11 | 75% | 65% | $0.39 b. | $0.38 b. | 13% | 17% |
| Eastern Europe and Central Asia | 26 | 21 | 14 | 12 | 54% | 57% | $0.14 b. | $0.11 b. | 5% | 5% |
| Latin America and the Caribbean | 32 | 30 | 11 | 17 | 34% | 57% | $0.16 b. | $0.19 b. | 5% | 9% |
| Middle East and Northern Africa | 14 | 18 | 8 | 5 | 57% | 28% | $0.15 b. | $0.09 b. | 5% | 4% |
| South West Asia | 14 | 12 | 6 | 7 | 43% | 58% | $0.10 b. | $0.22 b. | 3% | 10% |
| Total: | 174 | 159 | 94 | 85 | 54% | 53% | $3.06 b. | $2.21 b. | 100% | 100% |
Further highlights of Round 9 include the following:
| Purchase/payment category | Round 8 | Round 9 |
| Health products and health equipment | 36% | 21% |
| Medicines and pharmaceutical products | 11% | 13% |
| Training | 9% | 10% |
| Human resources | 8% | 14% |
| Infrastructure and other equipment | 8% | 10% |
| Procurement and supply management costs | 6% | 4% |
| M&E | 5% | 7% |
| Communication materials | 4% | 4% |
| Planning and admin | 3% | 5% |
| Living support to clients and target populations | 3% | 4% |
| Technical and management assistance | 3% | 3% |
| Overheads | 3% | 4% |
| Other | 1% | 1% |
No comments yet. Be the first to comment!